The Atlantic

Readers Discuss Extreme Drug Prices—And What to Do About Them

“The public should receive a cut of any drug profits, just as any other investor might.”
Source: Bryan Woolston / Reuters

Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up

Many pharmaceutical companies claim that exorbitant drug costs—some companies charge patients $100,000, $200,000, or even $500,000 a year—are necessary to fund expensive research projects that generate new drugs.

But “invoking high research costs to justify high drug prices,” Ezekiel J. Emanuel wrote last week, “is deceptive.” As even some pharmaceutical executives have acknowledged, he said, “there is no necessary link between a decline in drug prices and a decline in R&D.”


Too many people are focused on driving health costs down. It sounds intuitive, but it misses a bigger opportunity: making health costs most effective.

You're reading a preview, sign up to read more.

More from The Atlantic

The Atlantic4 min readPolitics
Trump Takes A Back Seat To Policy At The Democratic Debate
The president dominates every aspect of American politics, but you wouldn’t have known that from watching the first batch of candidates last night.
The Atlantic10 min readSociety
Tracing the Internal Queer Revolution
Riots and parades have made LGBTQ people visible. But a new anthology of writings from before, during, and after Stonewall shows the inward changes as more essential.
The Atlantic3 min readSociety
How Do Rich Neighborhoods Exist So Close to Poor Ones?
The research of the Harvard economist Raj Chetty shows that the scale of inequality is incredibly small.